Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company to keep an eye on for Todos partnership.
https://hephaistos.ai/about-us/
Gerald confirmed debt deal still due to close this quarter. Won't be surprised if it slips, but that's good news.
Likely dragging it out a bit to coincide with possible 3CL developments to keep options open.
It wasn't a lie, the train just came off the tracks. Since you failed to mention the very relevant news from just 2 months after that tweet, sharing the deal with Anavex for others to see below.
Relevant for Todos today since Anavex is still in the same business, only today its market cap is $664M versus it's 2014 market cap of around $20M...
Oh ya, and once these results are published there will be 2 additional trials, both hopefully with outstanding results, proving Lympro's value, not to mention this time we already have the team put together that can actually service clinical trials screening for BPs. See if you weren't so biased, you'd be providing a valuable service to the board with your extensive historical knowledge.
https://www.globenewswire.com/news-release/2015/02/18/707563/27474/en/Amarantus-Announces-First-Alzheimer-s-Biomarker-Services-Collaboration-for-LymPro-Test-R-With-Anavex-Life-Sciences-Corp.html
Thoughts from the update, which someone said has no new info as if Reg D announcement was not a critical new piece of information. If they're really targetting a NASDAQ listing later this year, Tollovid and Testing revenue must really be adding up this quarter. A new batch of Tollovid is not cheap, their materials run last year was several million dollars. Good they've been able to do this without financing.
Reg D. This is a worrisome funding route to me. I assume they're thinking they've got enough doctors with net worth interested now, but I really doubt it. And I imagine NLC folks and other adversarial actors are clamoring to work together so that those forces will take over majority interest in the company. That's why it sucks we only got 52% instead of 60%. We need to raise $10M as part of the 3CL agreement. 100 doctors at $100k each. If we FAIL to do this by September 15th of this year, NLC can take all the IP back. CAN, not WILL. If we FAIL to do this by end of March 2023, 3CL can raise funds independently and NLC with end up the controlling minority interest in the company.
I think it's clear the company isn't making enough money though to move Tollovir P2/3 forward. That's the missing piece, not so much the information. If they could they would.
Lympro enrollment "basically" complete... why the modifier? Is it done or not? AAIC is end of July, but ASIC not until November, so it would be awesome if they had topline results before July and the study by November.
Is this a troll post? Cuz I'm triggered that's hilarious JP
Yes, Huffman is CEO. That's a legacy typo of electronic signatures, we've seen it before.
Two new publications on MANF last week:
1.MANF in NASH,
Mesencephalic astrocyte-derived neurotrophic factor alleviates non-alcoholic steatohepatitis induced by Western diet in mice.
https://pubmed.ncbi.nlm.nih.gov/35567505/
2. MANF in Ischemic Brain Injury
The Unconventional Growth Factors Cerebral Dopamine Neurotrophic Factor and Mesencephalic Astrocyte-Derived Neurotrophic Factor Promote Post-ischemic Neurological Recovery, Perilesional Brain Remodeling, and Lesion-Remote Axonal Plasticity
https://pubmed.ncbi.nlm.nih.gov/35583716/
High volume last week, but not dilution...hmmmm
"I don't want anything to do with Gerald Commissions"
10,000 comments over the last 5 years say otherwise.
This security has a lot to offer.
Same old same old from JP. We will survive, we will win. Doesn't matter what price you pull the trigger at down here, you will make money in whatever medium to long range time frame you prefer.
Ok last week we did see dilution, 17M shares worth, now 482M O/S.
Here was the last meaningful update from the company on MANF in 2018. So much science and IND preparation has been done since then.
MANF Therapeutics
MANF Therapeutics continues to amass a tremendous portfolio of intellectual
property covering the use of MANF in the treatment of a range of disorders.
While still in pre-clinical development, the next major step for this program
is the appointment of a Chief Medical Advisor who can help finalize the
selection of the initial indication for first-in-man studies with MANF, and
drive the program towards the clinic. There is significant reason to believe
that successful first-in-man studies with MANF could have a dramatic impact on
the rNPV of the MANF asset, as positive efficacy in one indication likely
increases the potential of a positive outcome in other, potentially larger,
indications. Amarantus has continued to work with key groups, including the
Snow Foundation focused on developing new treatments for Wolfram's Syndrome,
to advance the science underpinning MANF so that upon proper capitalization
this asset can be swiftly moved to complete IND-enabling studies in
preparation for first-in-man. Amarantus continues to believe that MANF is
potentially the most valuable asset in the Amarantus portfolio and the Company
will continue to invest in the IP underpinning MANF until such time that MANF
Therapeutics can independently finance its development. With potential
disease-modifying applications in Glaucoma, Parkinson's disease, Alzheimer's
disease, myocardial infarction and diabetes, human proof of concept with MANF
in an orphan indication would significantly drive the rNPV for MANF by
establishing a reasonable risk adjusted discount to its value in the event of
success in these larger indications.
Yes, despite your predictions of bankruptcy, AMBS will be restarting operations soon, relieved of 2/3 of it's liabilities. Did you see Dr. Fumi Urano from Washington University St. Louis post an anticipated start date for MANF Phase 1 trial in 2024?
Once AMBS gets traction, it will be too late for anyone of modest means to accumulate a life changing stake. Hope you see past this current toxic exit.
Haven't forgotten any of the past, but I'm also not living in the past. Heal yourself.
Valuations are bought and paid for by the company. But it's a third party that generates them. Will not change the stock price. So why did company purchase? Because every partnering and investing firm does the same and we need a solid position to negotiate from. It's company friendly, but professional and it's a sign of good things going on in the background. Everyone should feel good that even if 3CL is worth 1/10th of that, TOMDF is still severely undervalued at a penny.
Fine as ever JP the price simply does not matter down here, for more than 5 years this has been a zero or hero ticket, and it ain't zero yet, despite your predictions.
What do you think about the news ThugMuffin?
Really stretching the phrase "bring to the table" LOL but good link
Well we'll well, ZERO dilution AGAIN last week despite the expert's opinion.
Pray tell, where does this volume come from if not dilution? Exit the cretins....
No it's not.
Why don't you wait for Monday when share count is reported? Hasn't been any dilution since December, that's a fact. Likely Toxics moving out of their common stake.
Very interesting. NO DILUTION last week (or since December) despite the major volume.
https://www.otcmarkets.com/stock/AMBS/security
We will see if this is dumping, dilution or just an exchange for cash. We need to pay Boyce $500k to close this deal. EMA still has shares to convert. Doubt this is "dumping" with the bids sitting out there all day consistently. Irrelevant to the long-term situation. Also pretty irrelevant for the price, it seems to execute at pace and market level.
He needs help ???
I agree, but I think it will take some time. Now that the intention is known to clean this up, I'm sure discussions will begin. The NDA with WilCarr that led to this began in 2020. Think about that.
of course they're going to add more debt, but it will be to actually kick off operations (maybe after another round of cleanup.)
We just walked ourselves back to 2014 with this exchange. It's a rebirth except MANF and Elto are more viable than ever and Management has an extra 7 years of networking and experience.
Not repeating, but yes, unfortunately under some similar pressure he has failed to protect common shareholders again. Eyes too big for stomach, I'll give you that, but also if that NOAH labs hadn't screwed him out of $4M this wouldn't be happening. Naive that he didn't hang on to more protection, but that does not make him a bad actor. He's corrected many things since last time.
Oh, and btw, this is the AMBS board. Keep it on subject.
Yes, stuff from 2015, like that tweet, or even worse, those blog posts, we're all prospective and we're real things happening that collapsed before they could bear fruit due to bad financing. Going on 7 years old and you need to get over it.
Quit ignoring what is happening. Don Huffman is CEO and they just got rid of 2/3rds of debt and still have the best assets. What will it take for you to acknowledge progress?
What an old tweet. That plan failed. Long in the past. Get over it
MANF is in double or triple the number of studies today than it was when you first invested. I don't know what questions you have about the ESS Term Sheet. Perhaps if you list them I can answer them.
You're way off, AMBS will not have $17M in debt after this Cutanogen sale and more importantly than the amount of money, the number of financers we will be dealing with will be so much simpler. Anyone who wanted to invest/partner/jumpstart was looking into a snake pit. Soon that I'll be cleaned away and in the past.
Plans change, losers don't.
You're just going to skip over the announcement that cuts liabilities down to around $10M? LOL
You are witnessing the rebirth of a company around it's primary asset MANF. Hope you've been accumulating these obnoxiously cheap shares.
Note 8 --Sale of Subsidiary Company
On November 23, 2021, the Company and certain Convertible Note Holders (described as New Debt in Note 5) entered into a non-binding term sheet (the “Term Sheet”) for the sale of the Company’s subsidiary, Cutanogen Corporation, which holds certain Engineered Skin Substitute assets (ESS). This potential transaction between the Company and Convertible Note Holders will allow for the formation of a joint venture between the Convertible Note Holders and WilCarr Ventures or its Affiliate (“WilCarr”). The Convertible Note Holders have agreed subject to completion of satisfactory final documentation for WilCarr to become the development and implementation Partner and Financier for a joint Venture to further develop the ESS asset.
The material terms contained in the Term Sheet contemplate a transaction wherein the Company sells to the Convertible Debt Holders:
Subsidiary Cutanogen Corporation
50,000,000 shares of Todos Medical Ltd.
in exchange for the extinguishment of
a minimum of $13,867,474 and up to $17,719,810 in secured and unsecured convertible debt (the “Notes”)
$7,581,828 in accounts payable associated with ESS
25% of any funds received by the Note holders from the Joint Venture after the Convertible Note Holders and potentially other debt holders are fully repaid the value of the Notes
Note 9 – Subsequent Event
On March 20, 2022, the Company’s Board of Directors adopted the 2022 Amarantus and Subsidiary/Affiliates Incentive Compensation Plan and approved a second amendment of the Company’s Series A Preferred class of stock that will be convertible into common stock. 3000 Series A Preferred shares will be designated, with each 1 share representing a right to buy 0.01% (initially 13% and up to a total of 30%) of the outstanding common shares immediately prior to an uplist onto a national exchange (the Uplist), provided however that if a concurrent financing occurs with the Uplist, then the Series A conversion shall occur immediately prior to such financing. The Board created alternate provisions for conversion, the purpose of which is to attract additional highly qualified personnel and ensure further incentivization via partial conversions for the achievement of other key value enhancing corporate goals and milestones. The shares allowed to be purchased would not be saleable, at the option of the Company, for up to 9 months following the goal achievement
here you go guys, try harder next time
https://www.otcmarkets.com/otcapi/company/financial-report/326200/content
Also, though this filing is not on it because it's an OTC filing, thought you guys might benefit from a website like docoh.com
"Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period.
Awaiting information from third parties to complete financial statements and disclosures.
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or
Interim Report and 15 calendar days to post an Annual Report.]
4/15/2022
Any letters since? Nope? Ok then, looks like they corrected this almost a year ago.
10-k extension filed. Allegedly to allow finalization of 13D language, which could mean major news imminent in next two weeks.
More new research. MANF has therapeutic potential in treating alcohol neurotoxicity such as Fetal Alcohol Spectrum Disorders (FASD)
https://pubmed.ncbi.nlm.nih.gov/35254650/
you're mistaking CDNF and GDNF
and multiple studies point to MANF's superiority compared to both in neurological activities, though yes, I'm sure these things are more effective together
Herantis completed a human clinical trial on related CDNF for far less with a partner. So there's that. xCNDF via HER-096 should be in trials next year and potentially overcomes the BBB investment hurdle.
Yes, most of the indications on the MSG Board Intro above have rodent studies. That's what growing interest gets you.
Thought I'd spruce it up a bit. Any suggestions let me know. AMBS Board also spruced up. I think both companies about to have a very refreshing spring. Success is contagious.
GC tweeted about how even though the stock market hasn't positively re-valued Todos since Phase 2, other markets have. I suspect he's referring to institutional and venture markets. One to keep an eye on is "The Cancer Fund." Keep an eye out for this as we try to find the money from revenue or other sources to get the Videssa clinical trial going.
https://cancerfund.com/
MANF in APAP overdose and APAP induced Liver Injury
https://www.nature.com/articles/s41419-022-04555-9